Man Group’s Elicio Therapeutics ELTX Stock Holding History

Man Group’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,261	Closed	-$12K	–	2042
2022 Q3	$12K	Buy	+1,261	New	+$13.2K	﹤0.01%	1968

Other funds holding ELTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Man Group's ELTX Position: Q4 2022 in Review

Man Group sold out of Elicio Therapeutics (ELTX) in Q4 2022, closing a stake of 1,261 shares — an estimated $12K sold.

Man Group first reported a position in ELTX in Q3 2022 and held it in 1 quarter. The position peaked at $12K in Q3 2022. 30 funds tracked by Wall St. Rank hold ELTX as of Q4 2022.

Man Group reported no remaining Elicio Therapeutics position as of Q4 2022 after selling out during the quarter.
Man Group sold 1,261 Elicio Therapeutics shares in Q4 2022, an estimated $12K.
Man Group first reported a position in Elicio Therapeutics in Q3 2022 and held it in 1 quarter.
Man Group's Elicio Therapeutics position peaked at $12K in Q3 2022.
30 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.